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Infection with many viruses results in the selective shutoff of host protein synthesis. A common target for virus interference
with host protein synthesis is the cap-binding protein complex, eIF4F. The large subunit of the complex, eIF4G, is cleaved
upon picornavirus (except cardiovirus) infection. Infection with adenovirus and influenza virus causes dephosphorylation of
the cap-binding subunit, eIF4E. Recently, it has been shown that infection with poliovirus or encephalomyocarditis virus
activates 4E-BP1, which is a specific inhibitor of eIF4E. Here we show that early in adenovirus infection, 4E-BP1 and its
related protein 4E-BP2 are phosphorylated and hence inactivated. This is not consistent with a role of 4E-BPs in adenovirus-
induced shutoff, but could explain the increase in protein synthesis reported early in infection. Phosphorylation of 4E-BP1
and 4E-BP2 is consistent with earlier findings in adenovirus-infected cells on the activation of the protein kinase p70S6k,
whose phosphorylation lies on the same pathway as 4E-BPs, by E1A. Findings similar to those described here were reported
for 4E-BP1 by D. Feigenblum and R. J. Schneider (1996, Mol. Cell. Biol. 16, 5450–5457). q 1997 Academic Press
Translation initiation in eukaryotes is facilitated by the eral sites diminishes its interaction with eIF4E, resulting
in the relief of translational inhibition (2, 3). On the other5* cap structure (m7GpppX, where X is any nucleotide)
that is present at the 5* end of all cellular mRNAs, except hand, infection of cells with encephalomyocarditis virus
(EMCV) or poliovirus leads to dephosphorylation of 4E-organellar. The cap is bound by the translation initiation
factor eIF4E. eIF4E is a subunit of the cap-binding protein BP1 and increases 4E-BP1 binding to eIF4E, which would
contribute to the shutoff of host protein synthesis aftercomplex eIF4F, together with eIF4G (to which eIF4E
binds directly) and eIF4A. eIF4F, in conjunction with an- infection (8).
Picornavirus RNAs are naturally uncapped and initiateother initiation factor, eIF4B, exhibits ATP-dependent
RNA helicase activity which is mediated by the eIF4A translation by a cap- and eIF4E-independent mechanism
by which ribosomes bind directly to an internal ribosomesubunit (1). eIF4E is a phosphoprotein which is limiting
in quantity in cells relative to other factors and ribo- entry site (IRES) (9–11). Picornaviruses inhibit cap-de-
pendent translation of cellular mRNAs, either by cleavingsomes. Its phosphorylation state positively correlates
with the growth status of the cell (1). eIF4E activity is also eIF4G (11) and/or by dephosphorylating 4E-BP1 (8). Al-
though adenovirus mRNAs do not possess an IRES,regulated by a family of small cellular proteins (known as
eIF4E-binding proteins or 4E-BPs) that bind to it and in- mRNAs expressed from the major late promoter (MLP)
are translated in cells superinfected by poliovirus, indi-hibit its activity (2, 3). Inhibition is the result of competition
with eIF4G for binding to eIF4E (4), as eIF4G shares a cating that these mRNAs exhibit a reduced requirement
for eIF4F for translation (12). The major late mRNAs initi-common site with 4E-BPs for binding to eIF4E (5). Consis-
tent with these findings, 4E-BP1 and 4E-BP2 inhibit cap- ate translation by a ribosome shunt mechanism (13).
Consistent with the cap-independent translation of thedependent, but not cap-independent, translation both in
vitro and in vivo (2). late mRNAs, eIF4E is dephosphorylated upon adenovirus
infection, coincident with the inhibition of host protein4E-BP1 (also called PHAS-I, for phosphorylated heat-
and acid-stable protein regulated by insulin), was first synthesis (14).
We wished to determine whether 4E-binding proteinsdescribed in the early 1980s as a major phosphorylation
target in cells in response to treatment with insulin and are dephosphorylated in adenovirus-infected cells, simi-
lar to what was shown for picornaviruses. First, HeLagrowth factors (6, 7). Phosphorylation of 4E-BP1 at sev-
cells were infected with wild-type human adenovirus type
5 to assess 4E-BP1 phosphorylation at early times in1 To whom reprint requests should be addressed at the Department
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protein synthesis occurs (16–20 hr). Changes in the 4E-
BP2 forms were studied in parallel. In HeLa cells, two
bands were detected for 4E-BP2 (termed a2 and b2). As
for 4E-BP1, the hypophosphorylated species (a2) mi-
grated faster than the hyperphosphorylated (b2) form
(Fig. 2B; A.-C.G. and N.S., manuscript in preparation). At
the onset of infection, most of the 4E-BP2 existed as an
hypophosphorylated (a2) form. As noted for 4E-BP1, 4E-
BP2 was also shifted upward on the gel following adeno-
FIG. 1. Adenovirus effect on 4E-BP1 phosphorylation early in infec- virus infection, starting at 4 hr. The shift was complete
tion. (A) Heat-treated extracts were analyzed by Western blotting using at 12 hr, as seen for 4E-BP1 (Fig. 2B). In other experi-
a rabbit polyclonal antibody directed against 4E-BP1 as described in
ments, we observed a change in migration as early as(8). (B) Far-Western blotting was performed on the samples described
30 min after infection (data not shown). This effect wasin (A) using 32P-labeled eIF4E as a probe, as described (2, 8).
concomitant with the expression of the E1A protein, as
assessed by Western blotting (data not shown). Phos-
phorylation of 4E-BP1 and 4E-BP2 following adenovirusWestern blotting, using rabbit polyclonal antiserum spe-
cific for 4E-BP1 (8), which does not cross-react with 4E- infection caused a decreased affinity of both 4E-BPs to-
ward eIF4E, as determined by a Far-Western assay usingBP2 or a new member of the family, 4E-BP3 (data not
shown). The hyperphosphorylated (g and d) forms of 4E- 32P-labeled eIF4E as a probe. Binding of 4E-BP1 to eIF4E
was abrogated, but binding of 4E-BP2 was only partiallyBP1 exhibit slow mobility on SDS–polyacrylamide gels
relative to the unphosphorylated (a) and hypophosphory- reduced (approximately 40% of the control; Fig. 2C). The
significance of the residual binding of 4E-BP2 is not im-lated (b) species (2, 3, 8, 15). In mock-infected cells, three
major 4E-BP1 forms were detected (Fig. 1A; isoforms a, mediately clear. The decrease in 4E-BP1 binding to eIF4E
was also confirmed by m7GDP chromatography. Cell ex-b, and g). The bands corresponding to 4E-BP1 were
shifted upward as early as 30 min postinfection and the tracts were incubated on ice for 2 hr with m7GDP-agarose
resin as described before (2) and then washed exten-pattern of 4E-BP1 isoforms did not change any further
up to 3.5 hr after infection. A ‘‘Far-Western’’ analysis was sively. Precipitated material was resolved by SDS–PAGE
and analyzed by Western blotting with an anti-4E-BP1performed to ascertain that the faster migrating forms (a
and b), which correspond to the hypophosphorylated or antibody. Infection with adenovirus abrogated the recov-
ery of 4E-BP1 on a cap-analog resin, in parallel with theunphosphorylated (8, 15) forms, can interact with eIF4E.
The binding of 4E-BP1 to eIF4E was strong in the mock- mobility shift and the reduction of binding to the eIF4E
probe as measured by Far-Western (Fig. 2D). This isinfected cells and at the onset of infection, but was barely
detected as early as 30 min postinfection (Fig. 1B). Thus,
the result of the Far-Western analysis is consistent with
early phosphorylation of 4E-BP1 (Fig. 1B). The lower
band, whose intensity decreased in the Far-Western
analysis early in infection in parallel with 4E-BP1, albeit
less drastically, comigrated with 4E-BP2 (Fig. 1B), sug-
gesting that this protein is also a target for modification
by adenovirus.
Next, we performed a time course of infection in HeLa
cells to examine the phosphorylation status of 4E-BP1 or
4E-BP2 at late times after infection when the shutoff of
protein synthesis occurs. The pattern of 4E-BP1 and 4E-
BP2 isoforms was examined by Western blotting, using
a rabbit polyclonal antiserum against 4E-BP1 (8) or an
affinity-purified rabbit polyclonal antiserum to 4E-BP2
(the antibody against human 4E-BP2 does not cross-re-
act with 4E-BP1 nor with 4E-BP3; manuscript in prepara- FIG. 2. Adenovirus effect on 4E-BP1 and 4E-BP2 phosphorylation
tion). The 4E-BP1 isoforms were shifted upward already late in infection. (A) Heat-treated extracts were subjected to Western
blotting and probed with a polyclonal 4E-BP1 antibody. (B) Non-heat-at the first time point (4 hr postinfection), consistent with
treated extracts were subjected to Western blotting with an affinity-the results in Fig. 1 (Fig. 2A). The two faster migrating
purified polyclonal antibody directed against 4E-BP2. (C) Extracts pre-species of 4E-BP1 (a and b) gradually disappeared be-
pared and blotted as in (A) were probed with 32P-labeled eIF4E. (D)
tween 8 and 12 hr of infection and only the two slower Extracts (250 mg, not heat treated) were incubated with m7GDP resin
migrating forms (g and d) were detected at 12 hr, without (25 ml) as described (2). Precipitated material was subjected to SDS–
PAGE and Western blotting with an anti-4E-BP1 antibody.any further change at the time when the shutoff of host
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an E1A-deficient virus or with several E1A mutant viruses
(data not shown), consistent with the data of Feigenblum
and Schneider (16). These results indicate that E1A medi-
ates 4E-BP’s phosphorylation.
In summary, the results show that upon adenovirus
infection, 4E-BP1 and 4E-BP2 become hyperphosphory-
lated. This is the first report to document a change in
phosphorylation of 4E-BP2 following virus infection. As
opposed to the effect of the picornaviruses EMCV and
poliovirus (8), 4E-BP1 is not activated by infection, but
rather inactivated early in infection. One of the reasons
for this disparity could be explained by the difference
in life cycles between picornaviruses and adenovirus.
Poliovirus and EMCV life cycles are very short and shutoff
occurs therefore in the first few hours after infection.
In addition, translation of the genome of these viruses
proceeds by a cap- and eIF4E-independent fashion (11).
Adenovirus life cycle is much longer (18–24 hr). Adenovi-
rus gene expression proceeds in two phases: early and
late expression. Late expression is principally driven by
the MLP, which directs transcription of mRNAs that trans-
late in a cap-independent manner. However, adenovirus
early genes, such as E1A, which are detectable earlyFIG. 3. Incorporation of 32P into 4E-BP1 following adenovirus infec-
in infection, are translated in a cap-dependent fashion.tion. 4E-BP1 was immunoprecipitated from 32P-labeled cells (8) mock
infected, infected for 5 hr with wild-type adenovirus, or infected with a Therefore, an early increase in cap activity by inactivation
virus carrying a mutant E1A (dl 1101-1108/520). Proteins were sub- of the translational repressors 4E-BP1 and 2 is likely to
jected to SDS–PAGE, transferred onto a PVDF membrane, and autora- be of benefit to the virus.
diographed (8).
Phosphorylation of 4E-BP1, following serum or insulin
stimulation, occurs through a PI3-kinase dependent, ra-
pamycin-sensitive pathway (1, 18). 4E-BP1 phosphoryla-similar to the situation observed after stimulation of cells
with insulin or growth factors. Although the results show tion coincides with the activation of p70S6k (18). p70S6k
does not phosphorylate 4E-BP1 directly (19) and doesthat 4E-BP1 and 4E-BP2 are most probably not involved
in the shutoff of host protein synthesis, the 4E-BPs could not appear to be upstream of 4E-BP1 (20). Indeed, trans-
fection of a rapamycin-resistant form of p70S6k does notplay a role in the increase of translation observed early
in adenovirus infection. This hypothesis is strengthened confer rapamycin resistance to 4E-BP1, as the case
would be if 4E-BP1 was a downstream target of p70S6kby the data of Feigenblum and Schneider (16), who
blocked the increase in translation following adenovirus (20). Furthermore, cotransfecting a wild-type form of
p70S6k together with 4E-BP1 reduced the phosphorylationinfection in 293 cells by incubation with rapamycin, which
prevents the phosphorylation of 4E-BP1 (15, 17, 18). of 4E-BP1 on rapamycin-sensitive sites (20), consistent
with the idea that p70S6k and 4E-BP1 compete for a com-To confirm that the changes in electrophoretic mobility
and in eIF4E-binding are due to the modulation of phos- mon upstream kinase. p70S6k is activated by the E1A
protein upon transfection (21), indicating that an elementphorylation, we performed 32P labeling of the HeLa cells
5 hr postinfection. 4E-BP1 was immunoprecipitated and in the PI3-kinase signal transduction pathway upstream
of p70S6k and 4E-BPs is the target for adenovirus. There-subjected to SDS–PAGE (8). In mock-infected cells, three
bands corresponding to the b, g, and d isoforms were fore, 4E-BP1 and 2 are not likely to be direct targets for
modification by the virus.resolved (Fig. 3, lane 1). Phosphorylation of 4E-BP1 is
increased following infection with wild-type adenovirus, Figure 4 summarizes the modifications involving
eIF4F in several viral infections. 4E-BP1 is the targetas evidenced by the increase in isoform d (total increase
2.5-fold). This increase in phosphorylation is not ob- for picornaviruses, which activate it, but also for adeno-
virus, which phosphorylates and inactivates it (as wellserved when a virus containing a mutant form of E1A (dl
1101-1108/520) (17) is employed (Fig. 3, lane 3). This as 4E-BP2).
In addition to the many functions of E1A in the cell,mutant contains deletions in the N-terminal domain of
E1A as well as in the CR2 (conserved region 2) and is including binding the cell-cycle regulators pRb, p107, and
p130, inactivating p27Kip1, and modulating transcription,deficient in binding to Rb family members, as well as to
other proteins such as p60cyclin A (17). The shift in 4E- E1A also acts as a modulator of 4E-BP1 and 4E-BP2, as
well as p70S6k. It remains to be determined whether theBP1 electrophoretic mobility was not detected either with
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FIG. 4. Modifications of eIF4F following infections with different viruses. Not shown is the effect of influenza virus that causes dephosphorylation
of eIF4E. X is a putative effector protein.
inactivation of 4E-BPs contributes to transformation by lational inhibitor, is also phosphorylated and inactivated
by adenovirus infection.Ad5 and to identify the virus direct cellular target in the
signal transduction cascade leading to 4E-BPs phos-
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